Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Turning stem cells homing potential into cancer specific drug delivery machines.

Literature DB >> 31576355

Turning stem cells homing potential into cancer specific drug delivery machines.

Nedime Serakinci^1,2, Huseyin Cagsin^1,2.

Abstract

Entities: Disease

Year: 2019 PMID： 31576355 PMCID： PMC6685889 DOI： 10.21037/atm.2019.06.30

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

Keyword Cloud
References

× No keyword cloud information.

10 in total

1. An engineered biomarker system to monitor and modulate immune clearance of cell therapies.

Authors: Amy Singleton; Danika Khong; Ling-Yee Chin; Shilpaa Mukundan; Matthew Li; Biju Parekkadan
Journal: Cytotherapy Date: 2017-09-13 Impact factor: 5.414

2. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines.

Authors: Christian Ries; Virginia Egea; Marisa Karow; Helmut Kolb; Marianne Jochum; Peter Neth
Journal: Blood Date: 2006-12-29 Impact factor: 22.113

3. Mesenchymal stem cells as therapeutic delivery vehicles targeting tumor stroma.

Authors: Nedime Serakinci; Rikke Christensen; Umut Fahrioglu; Flemming Brandt Sorensen; Frederik Dagnæs-Hansen; Miroslav Hajek; Tinna Herløv Jensen; Steen Kolvraa; Nicol W Keith
Journal: Cancer Biother Radiopharm Date: 2011-08-30 Impact factor: 3.099

4. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells.

Authors: Angela Kortesidis; Andrew Zannettino; Sandra Isenmann; Songtao Shi; Tsvee Lapidot; Stan Gronthos
Journal: Blood Date: 2005-01-27 Impact factor: 22.113

Review 5. Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas.

Authors: Kanya Honoki; Toshifumi Tsujiuchi
Journal: Expert Rev Anticancer Ther Date: 2013-08 Impact factor: 4.512

Turning stem cells homing potential into cancer specific drug delivery machines.

1. An engineered biomarker system to monitor and modulate immune clearance of cell therapies.

2. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines.

3. Mesenchymal stem cells as therapeutic delivery vehicles targeting tumor stroma.

4. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells.

Review 5. Senescence bypass in mesenchymal stem cells: a potential pathogenesis and implications of pro-senescence therapy in sarcomas.

6. Transformation of human mesenchymal stem cells in radiation carcinogenesis: long-term effect of ionizing radiation.

Review 7. Gleason Score 6 - Prostate Cancer or Benign Variant?

Review 8. Hallmarks of cancer: the next generation.

Review 9. Stem cell based gene therapy in prostate cancer.

Review 10. The challenge of targeting metastasis.